|
COPYRIGHT 2005 International Medical News Group
SAN FRANCISCO -- In a year's experience with the NuvaRing contraceptive, only 2.3% of women experience an expulsion of the device, according to the pooled results of four large, phase III clinical trials, Marc Kaptein, M.D., and Edio Zampaglione, M.D., reported in a poster presentation at the annual meeting...
Read the full article for free courtesy of your local library.
|